The effect of tibolone on the lipoprotein profile of postmenopausal women with type III hyperlipoproteinemia

Journal of Internal Medicine

Volumn 251, Issue 2, 2002, Pages 148-155

  De Beer, F ^a,b   Smelt, A H M ^b   Van Vark, L C ^a,b   Hoogerbrugge, N ^c   Havekes, L M ^a,b   Gevers Leuven, J A ^a,b,c  

^a TNO   (Netherlands)

^b LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^c ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

Hormone replacement therapy; Lipoproteins; Tibolone; Type III hyperlipoproteinemia

Indexed keywords

ANTILIPEMIC AGENT; APOLIPOPROTEIN E; CHOLESTEROL; GLYCOSYLATED HEMOGLOBIN; TIBOLONE; TRIACYLGLYCEROL; VERY LOW DENSITY LIPOPROTEIN CHOLESTEROL;

ADJUVANT THERAPY; ADULT; ARTICLE; BLOOD PRESSURE MONITORING; BLOOD SAMPLING; BODY MASS; BODY WEIGHT; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG INDUCED DISEASE; FEMALE; HUMAN; HYPERLIPOPROTEINEMIA TYPE 3; LIPID BLOOD LEVEL; LIPOPROTEIN BLOOD LEVEL; OUTCOMES RESEARCH; POSTMENOPAUSE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME; TRIACYLGLYCEROL BLOOD LEVEL;

CHOLESTEROL; CHOLESTEROL, VLDL; CLIMACTERIC; CROSS-OVER STUDIES; DOUBLE-BLIND METHOD; FEMALE; HUMANS; HYPERLIPOPROTEINEMIA TYPE III; LIPOPROTEINS; LIPOPROTEINS, VLDL; MIDDLE AGED; NORPREGNENES; TRIGLYCERIDES;

EID: 0036167274     PISSN: 09546820     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2796.2002.00944.x     Document Type: Article

References (46)

1. Apolipoprotein E: Genetic variants provide insights into it structure and function
2. Type III hyperlipoproteinemia (dysbetalipoproteinemia). The role of apolipoprotein E in normal and abnormal lipoprotein metabolism
3. Isoprotein specificity in the hepatic uptake of apolipoprotein E and the pathogenesis of familial dysbetalipoproteinemia
4. Rapid hepatic clearance of the canine lipoproteins containing only the E apoprotein by a high affinity receptor
5. Polymorphism of apolipoprotein E. II. Genetics of hyperlipoproteinemia type III
6. Normalization of receptor binding of apolipoprotein E2. Evidence for modulation of the binding site conformation
7. Abnormal lipoprotein receptor-binding activity of the human E apoprotein due to cysteine-arginine interchange at a single site
8. Polymorphism of apolipoprotein E and occurrence of dysbetalipoproteinemia in man
9. Morgagni lecture: Genetic polymorphism of apolipoprotein E - Impact on plasma lipoprotein metabolism
10. Apolipoprotein E2 transgenic rabbits. Modulation of the type III hyperlipoproteinemic phenotype by estrogen and occurrence of spontaneous atherosclerosis
11. Sex steroids and lipoprotein metabolism
12. Sex hormones and lipoprotein metabolism
13. Incidence of endometrial hyperplasia in postmenopausal women taking conjugated estrogens (Premarin) with medroxyprogesterone acetate or conjugated estrogens alone
14. The prevention of endometrial cancer in postmenopausal women with progestogens
15. Endocrinological studies with (7α,17α)-17-hydroxy-7-methyl-19-norpregn-5(10)-en-20-yn-3-one (Org OD 14)
16. Tibolone: A review
17. The effects of tibolone
18. Effects of postmenopausal estrogen replacement on the concentrations and metabolism of plasma lipoproteins
19. Effects of low dose oral contraceptives on very low-density and low-density lipoprotein metabolism
20. Effects of combined estrogen and progestin administration on plasma lipoprotein metabolism in postmenopausal women
21. Effects of low dosage progestin-only administration upon plasma triglycerides and lipoprotein metabolism in postmenopausal women
22. Lipoprotein, apolipoprotein, and lipolytic enzyme changes following estrogen administration in postmenopausal women
23. High density lipoprotein-2 and hepatic lipase: Reciprocal changes produced by estrogen and norgestrel
24. Regulation of hepatic lipase and serum lipoproteins by sex steroids
25. Effect of estrogen on very low density lipoprotein and low density lipoprotein subclass metabolism in postmenopausal women
26. Type III hyperlipoproteinemia: Paradoxical hypolipidemic response to estrogen
27. Effects of estrogen therapy on apolipoprotein E in type III hyperlipoproteinemia
28. A study of the hypolipidemic effect of estrogen in type III hyperlipoproteinemia
29. A rapid micromethod for apolipoprotein E phenotyping directly in serum
30. Apolipoprotein E genotyping on agarose gels
31. Cryopreservation with sucrose maintains normal physical and biological properties of human plasma low density lipoproteins
32. No effect of consumption of green and black tea on plasma lipid and antioxidant levels and on LDL oxidation in smokers
33. Nascent very-low-density lipoprotein triacylglycerol hydrolysis by lipoprotein lipase is inhibited by apolipoprotein E in a dose-dependent manner
34. No effect of β-carotene supplementation on plasma lipoproteins in healthy smokers
35. Lipoproteins in familial dysbeta-lipoproteinemia. Variation of serum cholesterol level associated with VLDL concentration
36. Tibolone and the serum lipid/lipoprotein profile: Does this have a role in cardiovascular protection in postmenopausal women?
37. Long-term effects of OrgOD14 on lipid metabolism in post-menopausal women
38. Tibolone: Influence on markers of cardiovascular disease
39. Short term blood pressure and metabolic effects of tibolone in postmenopausal women with non-insulin dependent diabetes
40. Metabolic effects of tibolone in postmenopausal women with non-insulin dependent diabetes mellitus
41. Effects of postmenopausal hormone replacement with oral and transdermal estrogen on high density lipoprotein metabolism
42. The role of the high-density lipoprotein receptor SR-BI in cholesterol metabolism
43. Mechanism of action/effects of androgens on lipid metabolism
44. The role of hepatic lipase in lipoprotein metabolism and atherosclerosis
45. Remnant lipoprotein metabolism: Key pathways involving cell-surface heparan sulfate proteoglycans and apolipoprotein E
46. Short-term oestrogen replacement therapy improves insulin resistance, lipids and fibrinolysis in postmenopausal women with NIDDM